A double blind, double dummy, randomised, multicentre study to compare the efficacy and safety of fulvestrant [Faslodex] 250mg with Arimidex [anastrozole] 1mg as a secondary-line therapy in postmenopausal women with oestrogen receptor positive advanced breast cancer

Trial Profile

A double blind, double dummy, randomised, multicentre study to compare the efficacy and safety of fulvestrant [Faslodex] 250mg with Arimidex [anastrozole] 1mg as a secondary-line therapy in postmenopausal women with oestrogen receptor positive advanced breast cancer

Completed
Phase of Trial: Phase III

Latest Information Update: 23 Apr 2013

At a glance

  • Drugs Fulvestrant (Primary) ; Anastrozole
  • Indications Advanced breast cancer
  • Focus Therapeutic Use
  • Sponsors AstraZeneca
  • Most Recent Events

    • 18 Dec 2007 Status changed from recruiting to completed.
    • 23 Oct 2006 New trial record.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top